"The driving passion he feels for his work links back to remestemcel-L, the experimental stem cell treatment he received at Duke in 2009 for graft-versus-host disease. Kooshesh’s transplant physician asked him to speak at an August 2020 FDA hearing that led to the drug being approved and becoming widely available. “It’s really one of the frontline therapies on the market. It's such an incredibly game-changing therapeutic because it demonstrates the power of stem cells in treating this kind of disease,” Kooshesh said in explaining the drug’s significance."
Except it's not on the market. That needs to change.
edit: they must have confused ODAC approval with drug approval
MESOBLAST CURES SR-aGVHD IN CHILDREN, page-50
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |